Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [11/06/2026 10:29 PST] Better Therapeutics, Inc (:BTTX), Up By 0% ($0) From $0 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [11/06/2026 10:29 PST] Better Therapeutics, Inc (:BTTX), Up By 0% ($0) From $0 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [11/06/2026 10:29 PST] Better Therapeutics, Inc (:BTTX), Up By 0% ($0) From $0 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [11/06/2026 06:03 PST] BTTX Expected to Trade Up After Bullish Patterns Develop
• [11/05/2026 06:48 PST] BTTX Expected to Trade Up After Bullish Patterns Develop
• [11/04/2026 06:00 PST] BTTX Expected to Trade Up After Bullish Patterns Develop